NEW YORK (GenomeWeb) – Wafergen Biosystems today priced a public offering of its securities that is expected to bring in $15 million in gross proceeds.

As part of the offering, Wafergen intends to issue 3.9 million shares of common stock, shares of preferred stock convertible into 11.1 million shares of common stock, and warrants to purchase 15 million shares of common stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.